Cannabis and Plasma Inflammation: Associations Are Not Treatment Effects

A study linked recent cannabis use with lower values of selected plasma inflammatory markers in groups defined by HIV status and lifetime methamphetamine use disorder. It did not randomly assign cannabis or demonstrate that cannabis treatment improved vascular or neurological outcomes.

Exposure definitions belong with the results

Rogers and colleagues analyzed 86 people with HIV receiving suppressive antiretroviral therapy and 148 people without HIV. Participants came from UC San Diego research studies conducted between 2009 and 2020. The main predictors included lifetime methamphetamine use disorder and past-month cannabis use.

Lifetime disorder and recent use are different time frames. Treating these labels as measurements of simultaneous drug concentrations would misdescribe the design. The study also did not isolate a standardized cannabis formulation, cannabinoid dose or route through random assignment.

Different markers showed different conditional patterns

The investigators measured plasma CXCL10/IP-10, CCL2/MCP-1, ICAM-1 and VCAM-1. Cannabis use was associated with lower CXCL10/IP-10 and conditionally lower values of other markers in specified groups. HIV status also modified some associations. A result for one marker or subgroup should not be generalized to every measured outcome.

The assays were performed in duplicate, and the analysis standardized marker values within plates to address batch differences. Those processing steps support a defined laboratory comparison; they do not turn a relative statistical association into a demonstrated clinical benefit.

Lower marker values are not a treatment trial

Participants’ health histories, treatment, substance-use patterns and selection into parent studies may relate to both cannabis exposure and inflammation. Statistical adjustment cannot guarantee removal of every alternative explanation. The design does not establish whether cannabis caused the measured differences.

Plasma marker values also are not direct measurements of brain inflammation, arterial injury or later disease events. The study supports hypotheses about conditional immune associations, while leaving efficacy, safety and clinical usefulness of a cannabinoid intervention unresolved.

Scientific source

Rogers JM and colleagues. Cannabis Use Moderates Methamphetamine- and HIV-Related Inflammation: Evidence from Human Plasma Markers. Viruses. 2025;17:1143. DOI: 10.3390/v17081143. This analysis uses the supplied observational report.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Short answer: Detecting an unexpected opioid at trace level does not, by itself, establish that a product contained an active adulterating dose. In a British Columbia drug-checking study, 189 of 8,889 samples not expected to include fentanyl had an unexpected opioid, and 61.4% of those detections were at trace concentration….

Spread the love

Read Article: Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Short answer: No. In coroner data analyzed for a Canadian study, nitazenes were present in 79 of 8,719 Ontario opioid deaths (0.91%) from January 2019 through December 2022. The Toronto subset was 33 of 1,803 opioid deaths (1.83%). These are presence counts in specified death records, not evidence that nitazenes…

Spread the love

Read Article: Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Why a GHB Result May Not Identify the Substance Originally Taken

Short answer: A test that reports GHB does not necessarily identify the substance a person originally took. A scientific review by Busardò and Jones explains that gamma-butyrolactone (GBL) and 1,4-butanediol can convert rapidly to GHB after ingestion. The measured GHB is a real analytical finding, but the starting compound is…

Spread the love

Read Article: Why a GHB Result May Not Identify the Substance Originally Taken

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us